• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge Trial

tetano

Editor, Senior Moderator
J Infect Dis


. 2025 Jun 20:jiaf331.
doi: 10.1093/infdis/jiaf331. Online ahead of print. Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge Trial

Yao Lu[SUP] 1 [/SUP], James D Allen[SUP] 2 [/SUP], Ted M Ross[SUP] 2 [/SUP], Benjamin Cowling[SUP] 3 [/SUP], Andreas Handel[SUP] 1 4 [/SUP], Kehinde Ogunyemi[SUP] 1 [/SUP], Katia J Bruxvoort[SUP] 5 [/SUP], Yang Ge[SUP] 1 [/SUP], Ye Shen[SUP] 1 [/SUP]



Affiliations
Abstract

Objective: Hemagglutination inhibition (HAI) titers are key correlates of influenza vaccine protection, yet a systematic comparison of HAI-based immunogenicity indicators is lacking for guiding vaccine development. This study aimed to compare these indicators by evaluating their correlation with influenza disease outcomes.
Method: We performed a secondary analysis of a mouse challenge study, in which 14 groups of mice were first challenged and received different H3N2 vaccines, and were subsequently infected with H3N2 (A/Kansas/14/2017). Disease outcomes were measured by weight loss and lung viral load. HAI titers were assessed against nine H3N2 strains, including the infecting strain, vaccine strains, and others, generating 11 HAI-based indicators considering the HAI titer was against the vaccine strains, the infecting strain, and the similarity between strains based on two antigenic distance algorithms. Correlations with disease outcomes were evaluated using linear regression models, with R-squared values and bootstrap resampling estimating variance.
Results: HAI titers against vaccine strains showed the weakest correlation with disease outcomes due to strain mismatch. The proportion of seroprotection among the nine strains demonstrated the strongest correlation, with R-squared values of ∼0.4 (weight loss) and ∼0.6 (lung viral load). Indicators based on antigenic distance were also predictive but not superior.
Conclusions: Relying solely on HAI titers against a single virus is insufficient for assessing influenza vaccine effectiveness. Calculating the proportion of seroprotection, a computationally efficient metric, offers robust predictive power and may be superior to traditional single strain titer even when it matches the infecting strain.

Keywords: Antigenic distance; Antigenic mismatch; Correlates of protection; Hemagglutination inhibition (HAI); Immunogenicity indicators; Influenza vaccine; Vaccine efficacy.

 
Back
Top Bottom